This Issue at a Glance

Atchison et  al (p. 676) set out to identify the sustained effects of anti-vascular endothelial growth factor (VEGF) drug injections on intraocular pressure (IOP). They analyzed 23 873 patients from the AAO IRIS Registry who received an intravitreous injection with aflibercept, bevacizumab, or ranibizumab in their right eyes between January 1, 2013 and December 31, 2015, and they used fellow, untreated eyes for comparison. Patients showed a statistically significant decrease in IOP, with a mean of 0.9 mmHg in treated eyes compared with an average decrease of 0.2 mmHg in fellow, untreated eyes.
Source: Ophthalmology - Category: Opthalmology Authors: Tags: This issue at a glance Source Type: research